34
Participants
Start Date
July 31, 2014
Primary Completion Date
June 30, 2015
Study Completion Date
June 30, 2015
Rilotumumab
Rilotumumab is a fully human monoclonal antibody immunoglobulin G, type 2 (IgG2) against human hepatocyte growth factor/scatter factor (HGF/SF) that blocks binding of HGF/SF to its receptor MET, inhibiting HGF/SF/MET-driven activities in cells.
Placebo
Placebo
Cisplatin
A platinum containing chemo-therapy compound that reacts in vivo, binding to and causing crosslinking of DNA, which ultimately triggers apoptosis (programmed cell death)
Capecitabine
A chemo-therapy prodrug that is enzymatically converted to 5-fluorouracil in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
Research Site, Nagoya
Research Site, Chiba
Research Site, Kashiwa-shi
Research Site, Matsuyama
Research Site, Fukuoka
Research Site, Sapporo
Research Site, Akashi-shi
Research Site, Kawasaki-shi
Research Site, Osaka
Research Site, Osaka
Research Site, Osakasayama-shi
Research Site, Suita-shi
Research Site, Takatsuki-shi
Research Site, Kitaadachi-gun
Research Site, Suntou-gun
Research Site, Utsunomiya
Research Site, Bunkyo-ku
Research Site, Goyang-si, Gyeonggi-do
Research Site, Hwasun
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Lead Sponsor
Amgen
INDUSTRY